Astute, Ortho-Clinical Diagnostics deal
Astute granted Ortho-Clinical Diagnostics exclusive, commercialization rights to the NephroCheck test and the Astute140 Meter in 11 countries in the EU and the U.S. The deal covers Austria, Belgium, France, Germany, Italy, Luxemburg, the Netherlands, Portugal, Switzerland, the U.K. and the Czech Republic. Astute also granted Ortho-Clinical semi-exclusive, worldwide rights to develop and commercialize a version of NephroCheck for use on Ortho-Clinical’s Vitros automated, high-volume testing platforms. The companies said the deal is semi-exclusive in that Astute can issue an undisclosed number of licenses to other companies that offer immunoassay systems. The companies said Ortho-Clinical made a $15 million equity investment in Astute, but are not disclosing further financial terms. ...